share_log

Phio Pharmaceuticals | 8-K: Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals | 8-K: Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals | 8-K：Phio 制药公布2024年第二季度财务业绩并提供业务最新情况
美股SEC公告 ·  2024/08/15 05:07

Moomoo AI 已提取核心信息

Phio Pharmaceuticals reported Q2 2024 financial results with cash position of $4.7 million as of June 30, 2024, down from $8.5 million at year-end 2023. The company secured additional $2.6 million through warrant exercises in July 2024. Q2 net loss decreased to $1.8 million from $2.5 million YoY, with R&D expenses down 37% to $0.9 million.The Phase 1b clinical trial for lead candidate PH-762 received positive safety recommendation, showing no dose-limiting toxicities or clinically relevant adverse events in the initial cohort. The trial is now enrolling for the second cohort with five clinical sites, including the newly added University of Pittsburgh Medical Center.Recent corporate updates include the appointment of Robert M. Infarinato as CFO, completion of a 1-for-9 reverse stock split, regaining Nasdaq compliance, and entering an exploratory collaboration with a global skin care company. The company also strengthened its patent portfolio with a new South Korean patent for INTASYL compounds targeting aging skin disorders.
Phio Pharmaceuticals reported Q2 2024 financial results with cash position of $4.7 million as of June 30, 2024, down from $8.5 million at year-end 2023. The company secured additional $2.6 million through warrant exercises in July 2024. Q2 net loss decreased to $1.8 million from $2.5 million YoY, with R&D expenses down 37% to $0.9 million.The Phase 1b clinical trial for lead candidate PH-762 received positive safety recommendation, showing no dose-limiting toxicities or clinically relevant adverse events in the initial cohort. The trial is now enrolling for the second cohort with five clinical sites, including the newly added University of Pittsburgh Medical Center.Recent corporate updates include the appointment of Robert M. Infarinato as CFO, completion of a 1-for-9 reverse stock split, regaining Nasdaq compliance, and entering an exploratory collaboration with a global skin care company. The company also strengthened its patent portfolio with a new South Korean patent for INTASYL compounds targeting aging skin disorders.
Phio Pharmaceuticals于2024年第二季度公布财务结果，截至2024年6月30日现金余额为470万美元，低于2023年底的850万美元。该公司在2024年7月通过认股权证行使额外获得260万美元。第二季度净亏损同比减少至180万美元，较去年的250万美元减少，研发费用下降37%至90万美元。用于主导候选药物PH-762的10亿期临床试验获得了积极的安全性推荐，在初始队列中未出现剂量限制性毒性或临床相关的不良事件。该试验现正招募第二队列，参与的临床地点包括新增加的匹兹堡大学医疗中心。近期公司更新包括任命Robert m. Infarinato为首席财务官，完成1比9的反向拆股，重新获得纳斯达克合规，并与一家全球护肤公司达成探索性合作。该公司还通过针对衰老肌肤疾病的新韩国专利，增强了其专利组合。
Phio Pharmaceuticals于2024年第二季度公布财务结果，截至2024年6月30日现金余额为470万美元，低于2023年底的850万美元。该公司在2024年7月通过认股权证行使额外获得260万美元。第二季度净亏损同比减少至180万美元，较去年的250万美元减少，研发费用下降37%至90万美元。用于主导候选药物PH-762的10亿期临床试验获得了积极的安全性推荐，在初始队列中未出现剂量限制性毒性或临床相关的不良事件。该试验现正招募第二队列，参与的临床地点包括新增加的匹兹堡大学医疗中心。近期公司更新包括任命Robert m. Infarinato为首席财务官，完成1比9的反向拆股，重新获得纳斯达克合规，并与一家全球护肤公司达成探索性合作。该公司还通过针对衰老肌肤疾病的新韩国专利，增强了其专利组合。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间